RPTR-168 / Repertoire - LARVOL DELTA

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma (clinicaltrials.gov) - P1/2 | N=7 | Terminated | Sponsor: Repertoire Immune Medicines | Trial completion date: May 2024 ➔ Oct 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: May 2024 ➔ Sep 2022; Development program terminated

Trial completion date • Trial primary completion date • Trial termination • Cervical Cancer • Cutaneous Melanoma • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1 • PRAME

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma (clinicaltrials.gov) - P1/2 | N=7 | Active, not recruiting | Sponsor: Repertoire Immune Medicines | Recruiting ➔ Active, not recruiting | N=24 ➔ 7

Enrollment change • Enrollment closed • Cervical Cancer • Cutaneous Melanoma • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1 • PRAME

Preclinical Research Published in Science Advances Demonstrates Repertoire Immune Medicines’ Cell-Tethering Technology Delivers Potent Interleukin-12 Directly to Solid Tumors Potentially Improving Effectiveness of Cellular Immunotherapies (Businesswire) - "Repertoire Immune Medicines announced today that Science Advances published preclinical research demonstrating the company’s cell-tethering technology can deliver the potent cytokine interleukin-12 (IL-12) to solid tumors without eliciting the severe systemic toxicities typically associated with the use of this cytokine. The research, conducted in mouse models, found that the use of cell-tethered IL-12 elevated anti-tumor activity in the immunosuppressive tumor microenvironment (TME)....Tumors have immunosuppressive microenvironments that can limit the efficacy of cellular immunotherapies used in cancer treatment. Immune-stimulating cytokines such as IL-12 have been shown to counter the immunosuppressive conditions within the tumor."

Preclinical • Oncology • Solid Tumor

Repertoire Immune Medicines Announces First Patient Dosed in Phase 1 Clinical Study of RPTR-168 (PRIME IL-12) for Relapsed or Refractory HPV-16-Positive Tumors (Businesswire) - “Repertoire Immune Medicines announced today that the first patient has been dosed in the company’s Phase 1 study of RPTR-168 (PRIME IL-12) in patients with select relapsed or refractory human papillomavirus (HPV)-16-positive tumors....The Phase 1 study is being conducted at trial centers in the United States. The first patient was dosed at HonorHealth Research and Innovation Institute in Scottsdale, Arizona.”

Trial status • Oncology

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Repertoire Immune Medicines; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cervical Cancer • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Torque presents preclinical data for lead deep-primed cellular immunotherapy programs at AACR 2019 special conference on Tumor Immunology and Immunotherapy (PRNewswire) - "...'The preclinical data we presented at this year's AACR Special Conference on Tumor Immunology and Immunotherapy demonstrate that co-administering Deep IL-12 Primed™ and Deep IL-15 Primed™ T cells directs the stimulatory activity of these cytokines to the tumor microenvironment and leverages their complementary biology to prime and boost the immune response of T cell therapies to achieve superior efficacy, with limited systemic exposure and toxicity'."

Preclinical

Torque presents new preclinical data for three deep-primed cellular immunotherapy programs, including newly unveiled deep TLR, at SITC 2019 Meeting (PRNewswire) - "Torque...new preclinical data for its lead Deep IL-15 Primed T cell, Deep Il-12 Primed T cell, and Deep TLR Primed T cell therapeutics programs as well as for the company's proprietary Slipstream™ process for manufacturing these first-in-class, multi-targeted cellular immunotherapies. The data are being presented today at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting being held November 6–10, 2019 in National Harbor, Maryland."

Preclinical